Palvella Therapeutics PVLA Transaction Costs Related To Reverse Merger Included In Accounts Payable And Accrued Expenses
Transaction Costs Related To Reverse Merger Included In Accounts Payable And Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept pvla:TransactionCostsRelatedToReverseMergerIncludedInAccountsPayableAndAccruedExpenses.
The official record: Palvella Therapeutics’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's transaction costs related to reverse merger included in accounts payable and accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's transaction costs related to reverse merger included in accounts payable and accrued expenses?
- Palvella Therapeutics (PVLA) reported transaction costs related to reverse merger included in accounts payable and accrued expenses of $0 in Q4 2025.
- How has Palvella Therapeutics's transaction costs related to reverse merger included in accounts payable and accrued expenses changed year-over-year?
- Palvella Therapeutics's transaction costs related to reverse merger included in accounts payable and accrued expenses decreased by 100.0% year-over-year, from $317.25K to $0.
- What does transaction costs related to reverse merger included in accounts payable and accrued expenses mean?
- Includes non-cash or accrued liabilities representing expenses incurred to facilitate a reverse merger transaction, such as professional fees, advisory costs, and regulatory filing expenses. These costs are distinct from operational expenses and reflect the one-time financial burden of corporate restructuring or public listing via merger. Identifying these costs allows stakeholders to isolate non-recurring transaction impacts from the company's core operating performance.